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Abstract 
Objective: Thalassemia along with hematopoietic stem cell transplantation (HSCT) can lead to major 
oxidative stress. Vitamins A and E are antioxidants which protect membrane from lipid peroxidation. We 
sought to determine for the first time, whether vitamins A and E supplementation is efficacious in maintaining 
or increasing plasma level of these vitamins in thalassemic children undergoing HSCT. 
Methods: A cross-sectional study was performed on 50 children with β-thalassemia major hospitalized for 
HSCT. Patients took a daily multivitamin. Plasma vitamins A and E levels were measured at four different 
times: on admission, HSCT day (day 0), day 7 and day 14 after HSCT. 
Findings: Plasma vitamin A and E were abnormal on admission in most patients (62.0% and 60.0% 
respectively). Ratio of patient with normal to abnormal plasma level of the vitamins improved from baseline 
to a peak on day 7 then deteriorated afterward until day 14. There was an increasingly positive correlation 
between daily oral intake and plasma vitamin A at different times, but plasma vitamin E showed inverse 
correlation at first which tended towards no correlation subsequently. In multivariate analysis, 
supplementation significantly changed plasma level of vitamin A at different measurement time (P=0.001) 
within study subjects. But, plasma level of vitamin E showed no significant difference (P=0.2). 
Conclusion: Our findings suggest that oral supplementation could have beneficial effects due to increasing 
plasma vitamin A level and preventing plasma vitamin E depletion. 
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Introduction 
Thalassemia is the most common congenital 
disease in the world[1], and thalassemia major is a 
severe and usually fatal kind of anemia[2]. 
Morphologic abnormality of erythrocytes in 
thalassemia exposes them to superior oxidative 
stress caused by globulin chains auto-oxidation, 
iron overload, low level of adult hemoglobin 
(HbA)[3], and lipid peroxidation[4]. Hematopoietic 
stem cell transplantation (HSCT) is the only 
available curative approach to thalassemia[4,5]. 
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HSCT is an aggressive therapeutic procedure 
which includes administration of high dose 
conditioning regimen (CR) followed by precursor 
hematopoietic stem cell infusion[2], with or 
without total body irradiation (TBI)[6]. HSCT is 
associated with the formation of large quantity of 
reactive oxygen/nitrogen species[6-8] mediated by 
free radicals forming oxidative products[9]. 
Therefore, thalassemic patients undergoing HSCT 
will certainly encounter a major and maybe 
cumulative oxidative stress condition which 
depletes critical plasma and tissue antioxidants[6]. 
Vitamin E is a lipid-soluble proxyl radical 
scavenger[10,11]. It is the major antioxidant 
protecting membrane lipid against peroxidative 
damages in plasma and erythrocytes[12]. Vitamin A 
is also an effective lipid soluble[12,13] oxygen 
quencher antioxidant and inhibits free radical 
reactions as well[12]. 
     A number of studies have assessed level of 
vitamin A and E in thalassemic patients[1,3,14,15]. A 
few have found a very low level of serum vitamin 
E[14] and a dramatic reduction in plasma vitamin A 
levels[15]. In two studies of vitamin A and E as 
supplementation, researchers observed 
considerable reduction in lipid peroxidation of 
erythrocyte membranes as outcome[1,3]. In 
addition, some studies on HSCT patients have also 
reported a decrease in serum concentration of 
some nutrient antioxidants such as α-tocopherol 
and β-carotene[7,16-18]. Livrea et al showed that 
administration of antioxidants by supple-
mentation of vitamin A and E could be advisable 
and beneficial in thalassemia[15]. Moreover, 
Durkens et al found that supplementation of 
antioxidants in HSCT patients could be effective[9]. 
Sabuncuoglu et al also claimed that vitamin 
supplementation was sufficient to maintain α-
tocopherol and β-carotene plasma levels after CR 
in children undergoing HSCT[19]. So, it can be 
expected that the administration of these 
supplements in thalassemic patients undergoing 
HSCT will also be advantageous. 
     As far as we know, there has been no research 
on vitamin A and E supplementation in this 
specific population, i.e. children with β-
thalassemia major undergoing curative HSCT. We 
aimed to find out further evidence on the effects of 
supplementation on maintaining adequate plasma 
levels of vitamin A and E to provide a rational 
basis for vitamin A and E administration. 
Subjects and Methods  
Study design and setting 
We carried out a prospective cross-sectional 
observational study in the Hematology-Oncology 
and Bone Marrow Transplantation Research 
Center at Shariati Hospital, Tehran, from July 2009 
to June 2011. Our institutional review board 
approved the study proposal. The study was 
approved by the Committee for Research Ethics 
and followed the Declaration of Helsinki. 
Participants 
Children aged 7.973.54 years with β-thalassemia 
major hospitalized for allograft HSCT in pediatric 
ward were recruited for this study. All patients’ 
guardians signed an informed consent before the 
study.  
Conditioning Regimen  
All patients received CR for allogenic HSCT. Their 
conditioning regimen consisted of Busulfan 
(3.5mg/kg for 4 days) and Cyclophosphamid (40 
mg/kg in thalassemia major class III and 50 mg/kg 
in thalassemia major class I and II for 4 days after 
Busulfan). Anti-Thymocyte Globulin (rabbit ATG, 
1.25mg/kg for 2 days before HSCT) was added for 
patients who received peripheral blood progenitor 
cells or with matched unrelated donors.  
Supplementation  
All 50 patients had the same nutritional intake 
based on the similar daily diet in the unit, and they 
all received food and medicine by mouth during 
the study and no patient went under total 
parenteral nutrition (TPN). All patients took a 
daily multivitamin (multi-Sanostol, Nycomed, 
Germany), started at the beginning of patients’ 
hospitalization after collecting baseline sample 
and it continued throughout their hospitalization, 
which was a part of institutional protocol. They 
received 40ml/day (containing 9600 IU vitamin A 
and 8 mg vitamin E), if their weight was more than 
20 Kg; and 20 ml/day (4800 IU vitamin A and 4 
mg vitamin E), if they were less than 20 Kg, both in 
two divided doses.  
Outcome measures 
 The study main outcomes were changes in 
vitamin A and E serum concentration levels; 
therefore we could evaluate the effect of 
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multivitamin administration in prevention of 
vitamin A and E concentration depletion in these 
patients. 
     We also categorized vitamin A levels of less 
than 0.2 µg/ml and vitamin E levels of less than 
5.0 µg/ml as “abnormal”, according to the 
laboratory normal range which was considered as 
the standard, and compared the normal to 
abnormal ratios. 
      We gathered baseline and clinical data during 
one month of observation. We measured plasma 
vitamin A and vitamin E levels at four different 
times: on admission (baseline), on HSCT day (day 
0), 1 week after HSCT (day 7), and 2 weeks after 
HSCT (day 14). 
Laboratory measurement of plasma levels of 
vitamins A and E 
 Four Blood samples (5ml) were collected from 
central venous catheters into a citrated blood 
collection tubes, then they were centrifuged for 10 
minutes at 1000×g. The plasma was separated in 
cryogenic vials then stored at -70 C till 
preparation for HPLC analysis. Final steps were 
performed in a semi dark room, away from the 
direct light. 150 μl internal standard (ethanolic 
retinol acetate 50 μg/ml) was mixed with 150 μl 
plasma by vortex-mixer for 30 seconds. Then 300 
μl hexane was added to the mixture and mixed 
again by vortex-mixer for 2 minutes. The Mixture 
was centrifuged at 6000×g for 5 minutes. 150 μl of 
the hexane layer (upper layer) picked out, and 
then the solvent was purged under nitrogen gas 
flow. Afterward 150 μl of mobile phase (95% 
methanol and 5% butanol) was added to vials, the 
transparent solution was ready for HPLC injection. 
All the procedure and sample storing were 
performed under light protected condition. Thirty 
minutes before sample injection the mobile phase 
was passed through the column. Twenty μl of 
samples were injected to HPLC column 
(2504.6mm) Pontosil C18; Knauer Inc. by auto 
sampler and Eurochrom 2000 software. Dual 
ultraviolet-visual light detection (sensitivity 
510¯) was used at the flow rate 5ml/min.      
Absorbance at 20 nm and 292 nm specified 
concentration of vitamin A and E respectively. 
Biases 
We included data from all thalassemic patients 
admitted for HSCT during the study period with 
no exclusion. Based on expert opinion, the case 
mix of admissions in our study time was 
comparable to other periods.  
     Standardized measurement protocols and 
calibration methods were developed and tested in 
order to minimize possible measurement errors. 
Statistical analysis 
Descriptive statistics were shown by frequencies 
and percentages for categorical variables and by 
mean+/- standard error for quantitative variables. 
For analysis of categorical variables, we used Chi-
square test and for quantitative variables Student 
t-test and Mann-Whitney-U test. 
     For comparison of vitamin E and A levels in 
different times of HSCT within subjects (i.e. 
baseline, day 0, day 7 and day 14), we conducted 
repeated measure analysis of variance (ANOVA) 
with pair-wise comparisons. Pearson correlation 
coefficient was calculated to compare levels of 
vitamin A and E levels at different two-by-two 
times. A P-value of less than 0.05 was considered 
significant. All statistical analysis was done using 
Statistical Packages for Social Sciences (SPSS) 
software version 16.0 (formerly SPSS Inc., USA, 
Chicago), for statistical analysis.  
Findings 
We gathered data from 50 patients. No patient 
died or was lost during follow-up. 
     Baseline and clinical data are summarized in 
Table 1. We calculated mean and standard error 
for plasma levels of vitamin A and E at 
differenttimes. Figs. 1 and 2 show trends of 
changes in plasma level of vitamin A and E. For 
both vitamins, we observed an increase from 
baseline to a peak on day 7; but, a decreasing 
trend was seen after day 7 until day 14. Plasma 
level of vitamin A was significantly different at 
different times of the study (P=0.001) within 
study subjects. But, plasma level of vitamin E 
showed no significant difference (P=0.2) (Table 2). 
There was an increasingly positive correlation 
between daily vitamin A oral intake and plasma 
level of vitamin A at different times. Daily vitamin 
E oral intake and plasma level of vitamin E showed 
inverse correlation at first which tended towards 
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Table 1: Plasma levels of vitamins: baseline, clinical and follow-up Data 
Variable  n (%) Mean SD 
Baseline Data 
Age (years) 50 (100.0) 7.98 3.54 
Gender                                          Male 26 (52.0)   
                       Female 24 (48.0)   
Body Mass Index (kg/m2) 50 (100.0) 14.98 1.59 
Clinical Data – Before HSCT 
Type of Thalassemia 
Class 1 14 (28.0)   
Class 2 20 (40.0)   
Class 3 14 (28.0)   
Sickle Thalassemia 2 (4.0)   
Source of Allograft 
Transplantation 
Peripheral Blood 29 (58.0)   
Bone Marrow 21 (42.0)   
Donor Type 
Sibling 42 (84)   
Unrelated  8 (16)   
Ferritin status (ng/Lit) 50 (100.0) 2221.9 1785.6 
Transfusion Start Time (months) 46 (92.0) 17.89  
Chelation Therapy Start Time (mo) 44 (88.0) 37.09  
Clinical Data – Conditioning 
regimen 
Bu, En 13 (26.0)   
Bu, En, ATG 37 (74.0)   
Clinical Data – Oral 
Supplementation 
Vitamin A (IU/d) 50 (100.0) 2500.8 866.1 
Vitamin E (mg/d) 50 (100.0) 2.1 0.7 
Clinical Data – After HSCT WBC engraftment time (days) 50 (100.0) 13.1 4.0 
   SD: Standard Deviation; HSCT: hematopoietic stem cell transplantation; Bu: Busulfan; En: Endoxan; ATG: Anti-Thymocyte Globulin  
no correlation at subsequent measurement times 
(Table 3). Ratio of normal to abnormal for plasma 
level of vitamin A, likewise vitamin E, increased 
from baseline to a peak on day 7; but, a decreasing 
ratio was seen after day 7 until day 14 (Table 4). 
Discussion 
Thalassemic patients undergoing HSCT, suffer 
from low plasma levels of vitamin A and E. In our 
study, plasma levels of vitamin A and E in most of 
our patients were abnormal at baseline (62.0% 
and 60.0% respectively). It seems that oral 
vitamin supplementation could have beneficial 
effects to maintain adequate plasma levels of these 
vitamins for this population at least in short-term 
use. It increased plasma vitamin A level and 
prevented plasma vitamin E depletion during 
admission for HSCT. 
Studies on thalassemia 
In the present study, we observed vitamin A and E 
deficiency at baseline, similar to other studies. 
 
Fig. 1: Mean (±standard error) plasma level of vitamin A 
at different times (µg/mm3) 
Fig. 2: Mean (±standard error) plasma level of vitamin E 
at different times (µg/mm3) 
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Table 2: Within subject difference of plasma levels of vitamin A and vitamin E at                                                                 
different times using repeated measure ANOVA 
Effect  Value F (Exact statistic) Error df Sig 
Vitamin A Wilks' Lambda .691 7.011 47.000 .001 
Vitamin E Wilks' Lambda .915 1.450 47.000 .240 
 
Livrea et al observed remarkable reduction of β-
carotene and α-tocopherol in thalassemic 
patients[15]. Decline or depletion of these vitamins 
can be explained by impairment of liver function 
and preoxidative process. Chronic hepatic iron 
overload causes a significant serum lipid 
reduction which can lead to simultaneous 
reduction in serum vitamin A and E[20,21]. 
Therefore we have a considerable 
hyperconsumption of vitamin E[15,20] as a radical 
scavenger[21] and possibly other lipid soluble 
antioxidants for neutralizing oxidative processes, 
both at liver [15, 21] and membrane level[14]. 
     Unlike our results, in one study no significant 
variation of vitamin A was observed[21]. One 
possible explanation is that severe liver damage 
might interfere with hepatic uptake or metabolism 
of β-carotene, which will cause a paradoxical 
relative elevation of β-carotene in serum of these 
patients[15]. 
     Das et al trial on thalassemic children using 
vitamin E supplementation for 4 weeks, reported 
no significant change in vitamin E serum level; but, 
as they took only one sample on the 29th day, they 
would not have been able to show any trend in 
vitamin E concentration during their 4-week 
follow-up. They discussed that gastrointestinal 
tract abnormality in absorption and ongoing 
consumption of a great amount of vitamin E for 
scavenging reactive mediator formed from 
oxidative stress may lead to observed results[2]. 
The former reason was later debated by 
Rachmilewitz et al[20]. In Rachmilewitz et al study, 
patients received a daily amount of 1050 IU 
vitamin E in a 16-month period. The authors 
reported almost four-fold increase in serum level 
of vitamin E after 14 months. Trends for serum 
level of vitamin E were different and opposite in 
some cases and the reason was not clear[20]. In 
comparison, the probable reasons that we did not 
see significant changes in vitamin E in our patients 
despite the HSCT procedure, might be the shorter 
time and lower oral dose of vitamin E 
supplementation regimen in our study. 
Studies on HSCT 
Two studies on patients undergoing HSCT 
reported that serum level of vitamin A and E was 
normal at baseline before CR[17,18]. The difference 
to our finding at the admission day could be due to 
difference in target populations as our study is 
focused solely on thalassemic patients. 
     High et al[17] assessed changes of vitamin A and 
E at 4 different times similar to our study. They 
report significant reduction of vitamin A from 
normal concentration at baseline until day 7. But 
our study showed a significant increase in vitamin 
A level until day 7 as a result of supplementation. 
They also found notable serum level of vitamin E 
depletion. But we did not observe any reduction in 
plasma level of vitamin E as supplementation 
result. They also discussed that plasma vitamin A 
and E spontaneously recover by day 14[17]. 
Probably because of patients’ underlying disease 
which resulted in vitamin deficiency at 
baseline[1,3,10,14,15], plasma level of vitamins would 
not reach completely normal values even after 
three weeks supplementation. 
Table 3: Correlation of daily vitamin A and E oral intake and plasma level of vitamin A and E at different times 
Corresponding plasma level of vitamin Baseline Day 0 Day 7 Day 14 
Daily Vitamin A Oral 
Intake 
Pearson Correlation Coefficient 0.101 0.275 0.378 0.389 
P. value 0.485 0.053 0.007 0.005 
Daily Vitamin E Oral 
Intake 
Pearson Correlation Coefficient -0.339 -0.182 0.017 -0.020 
P. value 0.016 0.207 0.909 0.889 
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Table 4: Ratio of normal to abnormal for plasma level of vitamin A and E at different times 
Variable Time Normal Abnormal Ratio 
Vitamin A 
Baseline 19 (38.0%) 31 (62.0%) 0.61 
Day 0 19 (38.0%) 31 (62.0%) 0.61 
Day 7 30 (60.0%) 20 (40.0%) 1.50 
Day 14 25 (50.0%) 25 (50.0%) 1.00 
Vitamin E 
Baseline 20 (40.0%) 30 (60.0%) 0.67 
Day 0 25 (50.0%) 25 (50.0%) 1.00 
Day 7 27 (54.0%) 23 (46.0%) 1.17 
Day 14 18 (36.0%) 32 (64.0%) 0.56 
 
      According to Goncalves et al, vitamin A and E 
decline on day 14 could be the result of increasing 
lipid peroxidation on day 10 as late effect of BuCy 
regimen[6]. Another possible cause could be 
vitamin status variation caused by poor intake in 
HSCT patients due to malabsorption[22,23], 
anorexia, nausea, vomiting and mucositis[23]. 
Chemotherapy-induced mucosal injury usually 
develops around day 7 and achieves its peak in 
two weeks (day 14)[24].  
     Sabuncuoglu et al observed a significant 
increase in vitamin E plasma level due to 
supplementation in HSCT patients. In comparison 
vitamin E supplementation dose was higher than 
in our study[19].    
     A few studies assessed total parenteral 
nutrition (TPN) in patients undergoing HSCT. 
They reported normal serum levels of vitamin A 
and E at baseline[7,18]. Clemens et al showed a 
significant reduction in α-tocopherol and β-
carotene during conditioning. Moreover, vitamin E 
supplementation and vitamin A and E dosages 
were not sufficient to maintain appropriate 
vitamin A and E status[18]. In contrast, our study 
showed a significant increase for vitamin A and a 
steady-state level of vitamin E during 
conditioning. This variation could be due to 
different age structure and fewer sample 
population in the study by Clemens et al. In 
another study by Jonas et al on 40 adult patients 
undergoing HSCT, changes in vitamin E level from 
baseline to day 14 was close to our results; they 
first faced an increase and then a reduction in 
serum level of vitamin E[7]. 
     We did not examine the level of oxidative stress 
factors such as lipid peroxidation of RBC in our 
study. Therefore the positive effects of 
supplementation on plasma levels of vitamins A 
and E on oxidative stress reduction is not known. 
Conclusion 
We found beneficial effects of vitamin A and E 
administration in thalassemic patients undergoing 
HSCT in order to prevent vitamin depletion. We 
recommend further studies to investigate the 
natural variation in plasma level of vitamin A and 
E without any supplementation, and thereafter, at 
least a well-designed clinical trial with longer 
follow-up period. 
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